BCR-ABL signaling is responsible for the pathogenesis of CML and is the primary molecular target for disease therapy with imatinib mesylate (Glivec, Gleevec, IM), a TK inhibitor. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.